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A 77-year-old female with recurrent non-small-cell lung cancer presented to a hospital outpatient clinic with tremor, weakness,
inability to coordinate motor movements, and confusion. It was suspected that the symptoms were due to possible central nervous
system metastases; however, a CT scan of her head was unremarkable. The lung clinic liaison pharmacist took a medication history
from the patient, complimented by extra information from the patient’s community pharmacy. The pharmacist suspected the rare
side eﬀect of serotonin syndrome was responsible for the patient’s presenting symptoms caused by the combination of oxycodone
and citalopram. The patient’s symptoms resolved soon after oxycodone was changed to morphine.
1.Introduction
Oxycodone is an opioid analgesic widely used in the
treatment of moderate to severe cancer-related pain. It is
available in immediate- and sustained-release oral formu-
lations. Depression is also a disabling comorbidity which is
common in patients with malignancies, particularly those
who have advanced or metastatic disease. It is estimated
that up to 15–25% of cancer patients suﬀer from depression
[1]. Citalopram is a selective serotonin reuptake inhibitor
licensed to treat the symptoms of depression.
2. Case Presentation
A 77-year-old female with recurrent non-small-cell lung
cancerpresented to the outpatient lung clinic complaining of
tremor, weakness, inability to coordinate motor movements,
and confusion. Central nervous system metastases were
suspected, and a CT scan of the head was ordered.
The patient’s medications were reported as oxycodone
(slow release) 50mg twice daily, oxycodone (immediate
release) 5mg when required, esomeprazole 40mg twice
daily, temazepam 10mg at night, and docusate 100mg with
sennosides 16mg twice daily. There was confusion as to
whether this list was complete.
A telephone conversation with the patient’s community
pharmacist revealed in addition to her reported medications
that she had recently picked up a repeat prescription of
citalopram20mgonceaday,afternothavingitdispensedfor
several months. Diazepam had also recently been prescribed
by her general practitioner for restless legs. The oxycodone
had been started several months earlier (rotated from
morphine) for cancer-related pain during the period that the
patient was not taking her citalopram.
Further discussion with the patient elucidated that the
symptoms started shortly after recommencing the citalo-
pram. The lung clinic pharmacist suspected a drug interac-
tion between citalopram and oxycodone which had resulted
in serotonin syndrome. Use of the Naranjo probability scale
indicated a probable relationship between the combination
of oxycodone and citalopram and the serotonin symptoms
[2]. The symptoms satisﬁed the Sternbach diagnostic criteria
for serotonin syndrome [3].
Oxycodone was changed back to morphine, and the
esomeprazole was reduced to 40mg daily (which in turn
should improve citalopram clearance). The symptoms2 Case Reports in Oncological Medicine
resolved within 48 hours, and the CT scan later came back
clear.
3. Discussion
Serotonin syndrome is a serious adverse reaction thought to
result from hyperstimulation of brainstem 5-HT1A and 2A
receptors[4].Coadministrationofoxycodonewithserotonin
reuptakeinhibitorshasonlyrecentlybeenassociatedwiththe
development of serotonin syndrome. An extensive literature
search revealed only four previous reports of serotonin
syndrome involving oxycodone [5, 6]. The opioids of the
phenylpiperidine series: pethidine, tramadol, methadone,
fentanyl, dextromethorphan, and propoxyphene are weak
serotonin reuptake inhibitors and are thus known to have
an association with serotonin symptoms [7]. Oxycodone is
a morphine analogue and so does not fall into this category
of opioids. An alternative explanation is required.
Oxycodone diﬀers from most other opioids in having
a signiﬁcant aﬃnity for kappa opioid receptors [8]. While
most of the drug is N-demethylated by CYP 3A4 to noroxy-
codone, approximately 10% is O-demethylated by CYP 2D6
to the very potent active metabolite, oxymorphone [8, 9].
Compared to oxycodone, oxymorphone has a higher aﬃnity
for the mu opioid receptor and is 14 times as potent as
oxycodone [10].
Other potential contributing factors for the drug interac-
tion include the following:
(i) a pharmacokinetic interaction between citalopram
and esomeprazole, reducing the citalopram clear-
ance. However, the patient had been on this combi-
nation for sometime without experiencing serotonin
eﬀects [11–13];
(ii) theinhibitionofCYP2D6bycitalopramaﬀectingthe
metabolismofoxycodone.However,thisinhibitionis
only classiﬁed as “weak” [9]. Available data indicates
that impaired activity of CYP 2D6 is associated with
only small changes in oxycodone pharmacokinetics,
which do not usually result in altered oxycodone
pharmacodynamics [14]. Also, if there were any
eﬀect, it would result in less of the active oxymor-
phone metabolite, rather than more;
(iii) opioids do not directly stimulate serotonergic neu-
ronal discharge but disinhibit neuronal activity by
suppressing GABA-mediated inhibition [15]. Thus,
the short-term eﬀect of morphine and perhaps other
opioids is to increase serotonin release in widespread
areas of the forebrain [16]. However, the patient had
been on the same dose of oxycodone for 3 months
prior to the onset of symptoms;
(iv) the patient may have been an extensive CYP 2D6
metaboliser. Whilst the metabolism of oxycodone
to oxymorphone via CYP 2D6 is not responsi-
b l ef o ra l lo ft h ee ﬀects of oxycodone, experi-
mental results indicate it does make a signiﬁcant
contribution in extensive CYP 2D6 metabolisers
[17].
Table 1
Drug Metabolised by CYP Inhibits CYP
Citalopram 3A4 2C19 1A2, 2D6, 2C19
(weak)
Esomeprazole 2C19, 3A4 2C19
Oxycodone 3A4 (to form noroxycodone)
2D6 (to form oxymorphone)
Table 1 summarises the activity of the relevant isozymes
of the hepatic cytochrome P450 system [9, 12–14].
4. Conclusion
Whilst serotonin syndrome is not listed as an adverse event
within the product information for OxyContin tablets when
given in combination with a selective serotonin reuptake
inhibitor, the small number of existing case studies to
date suggests that it is prudent to closely monitor patients
receiving this combination. The mechanism of interaction is
unclear and warrants further investigation.
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